The latest price target for KalVista Pharmaceuticals Inc (NASDAQ:KALV) was reported by HC Wainwright & Co. on May 1, 2026. The analyst firm set a price target for $27.00 expecting KALV to rise to within 12 months (a possible 0.04% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for KalVista Pharmaceuticals Inc (NASDAQ:KALV) was provided by HC Wainwright & Co., and KalVista Pharmaceuticals Inc downgraded their neutral rating.

There is no last upgrade for KalVista Pharmaceuticals Inc

The last downgrade for KalVista Pharmaceuticals Inc happened on May 1, 2026 when HC Wainwright & Co. changed their price target from $37 to $27 for KalVista Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharmaceuticals Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharmaceuticals Inc was filed on May 1, 2026 so you should expect the next rating to be made available sometime around May 1, 2027.

While ratings are subjective and will change, the latest KalVista Pharmaceuticals Inc (KALV) rating was a downgraded with a price target of $37.00 to $27.00. The current price KalVista Pharmaceuticals Inc (KALV) is trading at is $26.99, which is out of the analyst’s predicted range.